Literature DB >> 19464229

Complement component 5a (C5a).

Helga D Manthey1, Trent M Woodruff, Stephen M Taylor, Peter N Monk.   

Abstract

The 74 amino acid glycoprotein, complement component 5a (C5a), is a potent pro-inflammatory mediator cleaved enzymatically from its precursor, C5, upon activation of the complement cascade. C5a is quickly metabolised by carboxypeptidases, forming the less potent C5adesArg. Acting via a classical G protein-coupled receptor, CD88, C5a and C5adesArg exert a number of effects essential to the innate immune response, while their actions at the more recently discovered non-G protein-coupled receptor, C5L2 (or GPR77), remain unclear. The widespread expression of C5a receptors throughout the body allows C5a to elicit a broad range of effects. Thus, C5a has been found to be a significant pathogenic driver in a number of immuno-inflammatory diseases, making C5a inhibition an attractive therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464229     DOI: 10.1016/j.biocel.2009.04.005

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  56 in total

1.  Crystal structure of C5b-6 suggests structural basis for priming assembly of the membrane attack complex.

Authors:  Alexander E Aleshin; Richard G DiScipio; Boguslaw Stec; Robert C Liddington
Journal:  J Biol Chem       Date:  2012-04-12       Impact factor: 5.157

Review 2.  Antibody immunosuppressive therapy in solid organ transplant: Part II.

Authors:  Dusko Klipa; Nadim Mahmud; Nasimul Ahsan
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

3.  Cofactor regulation of C5a chemotactic activity in physiological fluids. Requirement for the vitamin D binding protein, thrombospondin-1 and its receptors.

Authors:  Glenda Trujillo; Jianhua Zhang; David M Habiel; Lingyin Ge; Mahalakshmi Ramadass; Berhane Ghebrehiwet; Richard R Kew
Journal:  Mol Immunol       Date:  2011-10-19       Impact factor: 4.407

Review 4.  Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals.

Authors:  Mirjana Bećarević
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 5.  Complement in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Jun Yuan; Min Chen; Ming-Hui Zhao
Journal:  Clin Exp Nephrol       Date:  2012-11-23       Impact factor: 2.801

6.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

7.  Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release.

Authors:  Eivind O Samstad; Nathalie Niyonzima; Stig Nymo; Marie H Aune; Liv Ryan; Siril S Bakke; Knut T Lappegård; Ole-Lars Brekke; John D Lambris; Jan K Damås; Eicke Latz; Tom E Mollnes; Terje Espevik
Journal:  J Immunol       Date:  2014-02-19       Impact factor: 5.422

8.  Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.

Authors:  D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

9.  A single functional group substitution in c5a breaks B cell and T cell tolerance and protects against experimental arthritis.

Authors:  Christoph Kessel; Kutty S Nandakumar; Francis B Peters; Varun Gauba; Peter G Schultz; Rikard Holmdahl
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

10.  The C5a anaphylatoxin receptor CD88 is expressed in presynaptic terminals of hippocampal mossy fibres.

Authors:  James W Crane; Gilang P Baiquni; Robert Kp Sullivan; John D Lee; Pankaj Sah; Stephen M Taylor; Peter G Noakes; Trent M Woodruff
Journal:  J Neuroinflammation       Date:  2009-11-16       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.